EHA Library - The official digital education library of European Hematology Association (EHA)

The role of innate immunity in MDS pathogenesis
Author(s):
David A. Sallman
Affiliations:
Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
EHA Library. List A. 06/14/19; 273698
Dr. Alan List
Dr. Alan List
Contributions
Learning Objectives
THIS MANUSCRIPT IS PUBLISHED AS AN OFFICIAL SUPPLEMENT OF HEMASPHERE.

Johanna Ungerstedt - Chair introduction

This session provides an update on the latest research and understanding of the impact of spliceosome mutations in Myelodysplastic syndromes (MDS), the role of innate immunity in the pathogenesis of MDS, and finally an update on how to clinically manage high-risk MDS patients after hypomethylating agent (HMA) failure.

Learning goals of the article
After this session, the audience will know the most common splicing factor mutations in MDS. Understand the molecular results of mutations in splicing factors. Knowledge of NLRP3 inflammasome activation in MDS. Be able to describe at least 5 mechanisms by which innate and inflammatory signaling could be targeted for treatment of MDS. Understand the definition of HMA failure/resistance. Know the prognosis of patients that have failed HMA. Understand and reason on the current recommendation is for the treatment of high-risk MDS after HMA failure/resistance.

Learning goals of the presentation
After attending this lecture, the participant will be able to
• understand the role of innate immunity in MDS pathogenesis,
• understand how cell-extrinsic and-intrinsic signals provoke NLRP3 inflammasome activation and pyroptosis leading to the hallmark pathological features of MDS, and
• understand the potential broad reaching importance of inflammasome activation as a diagnostic biomarker and therapeutic target in MDS patients.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies